THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.
THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES IN ABINGDON HEALTH PLC OR ANY OTHER ENTITY IN ANY JURISDICTION. NEITHER THIS ANNOUNCEMENT NOR THE FACT OF ITS DISTRIBUTION SHALL FORM THE BASIS OF, OR BE RELIED ON IN CONNECTION WITH, ANY INVESTMENT DECISION IN RESPECT OF ABINGDON HEALTH PLC OR ANY OTHER ENTITY.
THIS ANNOUNCEMENT SHOULD BE READ IN ITS ENTIRETY. IN PARTICULAR, YOU SHOULD READ AND UNDERSTAND THE INFORMATION PROVIDED IN THE APPENDICES.
THE CONTENT OF THIS ANNOUNCEMENT HAS NOT BEEN APPROVED BY AN AUTHORISED PERSON WITHIN THE MEANING OF THE FINANCIAL SERVICES AND MARKETS ACT 2000. RELIANCE ON THIS ANNOUNCEMENT FOR THE PURPOSE OF ENGAGING IN ANY INVESTMENT ACTIVITY MAY EXPOSE AN INDIVIDUAL TO A SIGNIFICANT RISK OF LOSING ALL OF THE PROPERTY OR OTHER ASSETS INVESTED.
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF THE DOMESTIC LAW OF THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (AS AMENDED) ("MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA THE REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
14 October 2025
Abingdon Health plc
("Abingdon Health", the "Group" or the "Company")
Result of Placing and Notice of GM
Abingdon Health plc (AIM: ABDX) a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, announces that, further to its announcement at 5:04 p.m. on 13 October 2025 (the "Announcement"), it has successfully completed and closed the Placing to raise gross proceeds of £3.3 million.
The Placing has conditionally raised gross proceeds of £3.3 million through the placing of 54,500,000 Placing Shares to certain institutional and other investors. As part of the Placing, Chris Hand, Executive Chairman of the Company, has agreed to subscribe for 500,000 Placing Shares, which is expected to raise £30,000.
In addition to the Placing, the Company is providing existing eligible shareholders with the opportunity to subscribe for up to 3,333,333 Retail Offer Shares at the Placing Price, to raise up to £200,000 (before expenses). No part of the Placing is conditional on the Retail Offer proceeding or on any minimum take-up on the Retail Offer. The launch of the Retail Offer is expected to occur shortly following this announcement.
The Placing Price of 6 pence represents a discount of 0.8 per cent. to the closing middle market price of 6.05 pence per Ordinary Shares on 10 October 2025, being the last business day prior to the Announcement of the Placing.
Zeus Capital Limited is acting as agent for and on behalf of the Company in respect of the Placing. The Placing was undertaken through an accelerated bookbuild process.
Related party transactions
As Octopus Investments Limited is a substantial shareholder in the Company, the allotment and issue of the Placing Shares constitutes a related party transaction for the purpose of the AIM Rules. The Directors (with the exception of Chris Hand who is taking part in the placing) consider, having consulted with Zeus Capital Limited, the Company's nominated adviser, that the terms of the participation in the Placing by Octopus Investments Limited is fair and reasonable insofar as its Shareholders are concerned.
General Meeting and Posting of Circular
The Fundraising is conditional upon, inter alia, the approval by the Shareholders of the Resolutions to be proposed at the General Meeting to be held at the offices of the Company at York Biotech Campus, Sand Hutton, York YO41 1LZ at 9.00 a.m. on 30 October 2025. A circular, containing further details of the Fundraising, notice of General Meeting and proxy form (together the "Circular") will be despatched to Shareholders shortly and will be available on the Company's website at https://www.abingdonhealth.com/investors/ .
Recommendation
The Directors consider the Resolutions being proposed at the General Meeting to be in the best interests of the Company and the Shareholders as a whole. Consequently, the Directors (including Chris Yates, co-founder of Abingdon Health plc, and President and Director of Abingdon Health USA Inc.) unanimously recommend that you vote in favour of the Resolutions to be proposed at the General Meeting, as they intend to do in respect of the 20,267,311 Existing Ordinary Shares held, directly or indirectly, by them representing approximately 10.5% per cent. of the total voting rights of the Company in issue.
Admission
Application will be made to the London Stock Exchange for admission of the New Ordinary Shares to trading on AIM ("Admission"). It is expected that, subject to the necessary resolutions being passed at the General Meeting, Admission will become effective and dealings in the new Ordinary Shares will commence at 8:00 a.m. on 31 October 2025. The new Ordinary Shares will be issued fully paid and will rank pari passu in all respects with the Company's Existing Ordinary Shares.
Admission is conditional, inter alia, upon Admission becoming effective, the Placing Agreement not having been terminated and becoming unconditional, and upon the approval of the Resolutions by the Shareholders at the Company's forthcoming General Meeting to be held on 30 October 2025.
Capitalised terms used but not defined in this announcement have the meanings given to them in the Company's announcement released at 5:04 p.m. on 13 October 2025 in respect of the Proposed Placing to raise up to £3.34 million (before expenses) and Retail Offer to raise up to £200,000 (before expenses) unless the context provides otherwise.
Dr Chris Hand, Executive Chairman of Abingdon Health plc, commented:
"I am delighted that we can announce the completion of this Fundraising. Our full service CDMO offering and recently established Abingdon Health USA are both resonating well with customers. This investment will allow us to execute larger projects and expand USA manufacturing activities to promote our growth. I would like to thank current shareholders for their tremendous support and welcome new shareholders to the Company."
Enquiries:
| Abingdon Health plc |
|||
| Chris Hand, Executive Chairman
|
Via Walbrook PR |
||
| T om Hayes, Chief Financial Officer
|
|
||
| |
|
||
| Zeus (Sole Broker and Nominated Adviser) |
Tel: +44 (0)20 3829 5000 |
||
| Antonio Bossi / Darshan Patel / Jacob Walker (Corporate Finance) |
|
||
| N ick Searle / Fraser Marshall (Corporate Broking)
|
|
||
| |
|
||
| Walbrook PR (Media & Investor Relations) |
Tel: +44 (0)20 7933 8780 or [email protected] |
||
| Paul McManus / Alice Woodings |
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 |
||
| |
|
||
About Abingdon Health plc
Abingdon Health Group is a leading med-tech contract service provider offering its services to an international customer base.
The Group's CDMO expertise offers lateral flow product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine manufacturing; from "idea to commercial success". Abingdon Analytical Ltd offers performance evaluation for lateral flow and other in vitro diagnostic assays from its Doncaster laboratory.
Founded in 2008, Abingdon Health is headquartered in York, England with laboratories in Doncaster, England and laboratories and commercial offices in Madison, Wisconsin, USA.
Abingdon Health's brochure outlines the comprehensive support the Group can now provide to its international customers. For more information visit: www.abingdonhealth.com .
Certain statements in this Announcement are forward-looking statements with respect to the Company's expectations, intentions and projections regarding its future performance, strategic initiatives, anticipated events or trends and other matters that are not historical facts and which are, by their nature, inherently predictive, speculative and involve risks and uncertainty because they relate to events and depend on circumstances that may or may not occur in the future. All statements that address expectations or projections about the future, including statements about operating performance, strategic initiatives, objectives, market position, industry trends, general economic conditions, expected expenditures, expected cost savings and financial results, are forward-looking statements. Any statements contained in this Announcement that are not statements of historical fact are, or may be deemed to be, forward‐looking statements. These forward-looking statements, which may use words such as "aim", "anticipate", "believe", "could", "intend", "estimate", "expect", "may", "plan", "project" or words or terms of similar meaning or the negative thereof, are not guarantees of future performance and are subject to known and unknown risks and uncertainties. There are a number of factors including, but not limited to, commercial, operational, economic and financial factors, that could cause actual results, financial condition, performance or achievements to differ materially from those expressed or implied by any of these forward‐looking statements. Many of these risks and uncertainties relate to factors that are beyond the Company's ability to control or estimate precisely, such as changes in taxation or fiscal policy, future market conditions, currency fluctuations, the behaviour of other market participants, the actions of governments or governmental regulators, or other risk factors, such as changes in the political, social and regulatory framework in which the Company operates or in economic or technological trends or conditions, including inflation, recession and consumer confidence, on a global, regional or national basis. Given those risks and uncertainties, readers are cautioned not to place specific reliance on forward-looking statements. Forward-looking statements speak only as of the date of this Announcement. Each of the Company and Zeus expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise unless required to do so by applicable law or regulation.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.